India, July 8 -- Wednesday, Chemomab Therapeutics Ltd. (CMMB) and Scipher Medicine Corporation announced a merger agreement to combine the companies, which will focus on advancing nebokitug, a first-in-class clinical stage anti-CCL24 antibody, into a Phase 2 trial for the treatment of rheumatoid arthritis.
As per the terms of the deal, the pre-merger Chemomab equity holders are expected to own approximately 32% of the combined company, which will operate as Scipher Medicine Corporation. Meanwhile, pre-merger Scipher equity holders are expected to own approximately 68% of the combined company, each on a fully-diluted basis and subject to adjustment.
Additionally, pre-merger Chemomab shareholders are expected to receive contingent value rig...